Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932799 · ClinicalTrials.gov registry record
Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing
A clinical trial of Opioid Use and Opioid-Related Disorders, sponsored by University of Washington.
- Completed
- Registry status
- 5,411
- Enrollment target
- 2
- Study locations
NCT03932799: Completed study of Opioid Use and Opioid-Related Disorders, sponsored by University of Washington.
NCT03932799 is a study of Opioid Use and Opioid-Related Disorders that has completed, run by University of Washington. The registered enrollment target is 5,411 participants, below the 148,209-participant average among 105 other Opioid Use trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03932799, a study of Opioid Use and Opioid-Related Disorders, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- 5,411 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study examines the comparative effectiveness of opioid review programs in reducing unsafe opioid prescribing in two states: prospective prior authorization (PA) with hard stops in Washington and retrospective review (RR) with prescriber notification in Ohio.
Primary Outcome
More than 7 unique days of opioids within the time period
Conditions Studied
Interventions
- OTHER Prospective prior authorization (PA) with hard stops in Washington
- OTHER Retrospective review (RR) with prescriber notification in Ohio
Study Locations (2)
Ohio
- The Ohio State University - Columbus
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,411 participants |
| Start Date | 2019-08-06 |
| Est. Completion | 2022-06-30 |
What the finished NCT03932799 record still lists
NCT03932799 is an observational study that tracks outcomes without assigning an intervention. Its 5,411 participants enrollment target places it among the larger protocols in the corpus, below the 148,209-participant average among 105 other Opioid Use trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Opioid Use appearing as the primary indexed condition, and to 2 interventions - of which Prospective prior authorization (PA) with hard stops in Washington is the first listed.
NCT03932799 reports a single indexed study location in Ohio, Washington.
Frequently Asked Questions
What is clinical trial NCT03932799 about?
NCT03932799 is a clinical study titled "Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing". This study examines the comparative effectiveness of opioid review programs in reducing unsafe opioid prescribing in two states: prospective prior authorization (PA) with hard stops in Washington and retrospective review (RR) with prescriber notification in Ohio.
What is the current status of trial NCT03932799?
This trial is currently completed. The enrollment target is 5,411 participants. The study started on 2019-08-06. Estimated completion is 2022-06-30.
What conditions does trial NCT03932799 study?
This clinical trial studies the following conditions: Opioid Use, Opioid-Related Disorders.
What interventions are being tested in trial NCT03932799?
The interventions under investigation include: Prospective prior authorization (PA) with hard stops in Washington (OTHER), Retrospective review (RR) with prescriber notification in Ohio (OTHER).
Who is sponsoring clinical trial NCT03932799?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03932799 being conducted?
This trial has 2 study locations across Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03932799's enrollment target sits among peer trials
5,411 5th of 105 higher than 101 of 105 other Opioid Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression
RECRUITING · Phase 3
-
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
RECRUITING · Phase 4
-
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
RECRUITING · Phase 3
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
QL vs LAI for Palatoplasty
RECRUITING · NA
-
Opioid Use After Laparoscopic Salpingectomy
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI